Spots Global Cancer Trial Database for advanced cancers
Every month we try and update this database with for advanced cancers cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Physician Perceptions About Parenteral Hydration in Latin America and Spain | NCT01011140 | Dehydration Advanced Cancer... | Survey | 18 Years - | M.D. Anderson Cancer Center | |
| Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma | NCT01983969 | Advanced Cancer... Lymphoma | Azacitidine Vorinostat Gemcitabine Busulfan Melphalan Dexamethasone Caphosol Glutamine Pyridoxine Rituximab | 15 Years - 65 Years | M.D. Anderson Cancer Center | |
| Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients | NCT00877773 | Advanced Cancer... | Temsirolimus | - | M.D. Anderson Cancer Center | |
| Hepatic Arterial Infusion (HAI) of Abraxane | NCT00732836 | Liver Cancer Advanced Cancer... Solid Tumors | HAI Abraxane Hepatic Artery ... IV Abraxane | 18 Years - | M.D. Anderson Cancer Center | |
| Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors | NCT01454804 | Advanced Cancer... | Pazopanib Lapatinib Trastuzumab (He... Pazopanib | - | M.D. Anderson Cancer Center | |
| Perception of Palliative Care Encounter | NCT02558257 | Advanced Cancer... | Survey | 18 Years - | M.D. Anderson Cancer Center | |
| Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients | NCT00877773 | Advanced Cancer... | Temsirolimus | - | M.D. Anderson Cancer Center | |
| Indwelling Pleural Catheter With Either Doxycycline or Saline at Day 7 for Pleurodesis | NCT02623959 | Advanced Cancer... Malignant Pleur... | Questionnaires Fentanyl Patch Fentanyl (IV) Saline Doxycycline Phone Calls | 18 Years - | M.D. Anderson Cancer Center | |
| Personalized Oncogenomics (POG) Program of British Columbia | NCT02155621 | Metastatic Canc... Advanced Cancer... Cancers That Ca... | Genome sequenci... | 18 Years - 85 Years | British Columbia Cancer Agency | |
| Patient-Reported Outcomes-Based Palliative and Hospice Care Practice: A Usability Study | NCT01024166 | Advanced Cancer... | Questionnaire a... Questionnaire a... | 21 Years - | M.D. Anderson Cancer Center | |
| Plasmodium Immunotherapy for Advanced Cancers | NCT03375983 | Advanced Cancer... | Blood-stage inf... | 18 Years - 70 Years | CAS Lamvac Biotech Co., Ltd. | |
| A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies | NCT02571036 | Gastrointestina... Advanced System... Advanced Cancer... | DCC-2618 DCC-2618 | 18 Years - | Deciphera Pharmaceuticals LLC | |
| TTP607 in Refractory Solid Malignancies | NCT00939172 | Advanced Cancer... Lymphoma | TTP607 | 18 Years - | M.D. Anderson Cancer Center | |
| Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer | NCT01548144 | Advanced Cancer... | Crizotinib (Xal... Pazopanib Pemetrexed | 18 Years - | M.D. Anderson Cancer Center | |
| End of Life Treatment Preferences of Latino Medicare Beneficiaries With Cancer | NCT01389830 | Advanced Cancer... | Telephone Surve... | 18 Years - | M.D. Anderson Cancer Center | |
| Dexamethasone Dyspnea Study | NCT01670097 | Advanced Cancer... Hematologic Dis... Solid Tumors | Dexamethasone Placebo Questionnaires Spirometer Phone Calls | 18 Years - | M.D. Anderson Cancer Center | |
| A First in Man Study of MABp1 in Patients With Advanced Cancers | NCT01021072 | Advanced Cancer... | MABp1 | 18 Years - | Janssen Research & Development, LLC | |
| Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer | NCT01048008 | Advanced Cancer Brain Involveme... | DM-CHOC-PEN | 18 Years - | DEKK-TEC, Inc. | |
| Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer" | NCT01976910 | Advanced Cancer | DM-CHOC-PEN | 18 Years - | DEKK-TEC, Inc. | |
| Self Reported Deviations From Opioid Analgesic Prescription | NCT00907192 | Advanced Cancer... | Personal Interv... Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| Occupational Therapy in Palliative Care | NCT02521194 | Advanced Cancer... | Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| The Use of Light Therapy for Managing Sleep Disturbances in Patients With Advanced Cancer | NCT01193530 | Advanced Cancer... | Bright Light Th... Dim Red Light T... Questionnaires Study Diaries Red Light Liteb... Bright Light Li... | 18 Years - | M.D. Anderson Cancer Center | |
| Erlotinib in Combination With Pralatrexate in Advanced Malignancies | NCT01532011 | Advanced Cancer... Solid Tumors | Erlotinib Pralatrexate | 12 Years - | M.D. Anderson Cancer Center | |
| Erlotinib in Combination With Cetuximab | NCT00895362 | Advanced Cancer... | Erlotinib Cetuximab | 18 Years - | M.D. Anderson Cancer Center | |
| Sublingual Fentanyl for the Management of Breakthrough Pain | NCT02514252 | Advanced Cancer... | Fentanyl Sublin... Questionnaires Mental Ability ... Study Diary | 18 Years - | M.D. Anderson Cancer Center | |
| Tolvaptan in Hyponatremic Cancer Patients | NCT01199198 | Advanced Cancer... | Tolvaptan Placebo | 18 Years - | M.D. Anderson Cancer Center | |
| High Flow Oxygen and Bilevel Airway Pressure for Persistent Dyspnea in Patients With Advanced Cancer | NCT00934128 | Advanced Cancer... | Vapotherm BIPAP | 18 Years - | M.D. Anderson Cancer Center | |
| Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors | NCT02478320 | Advanced Cancer... | Ilorasertib | 18 Years - | M.D. Anderson Cancer Center | |
| Azacytidine and Valproic Acid in Patients With Advanced Cancers | NCT00496444 | Advanced Cancer... | Azacitidine Valproic Acid | 2 Years - | M.D. Anderson Cancer Center | |
| Regorafenib and Cetuximab in Patients With Advanced Malignancy | NCT02095054 | Advanced Cancer... | Regorafenib Cetuximab Questionnaire | 12 Years - | M.D. Anderson Cancer Center | |
| Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038) | NCT00836927 | Advanced Cancer... | Ridaforolimus T... Ridaforolimus I... | 1 Year - | Merck Sharp & Dohme LLC | |
| Changes in Patient Reported Constipation Among Advanced Cancer Patients After Receiving an Educational Intervention | NCT02422329 | Advanced Cancer... | Questionnaires Video Fact Sheet | 18 Years - | M.D. Anderson Cancer Center | |
| Message 2: The Effect of Message Content and Clinical Outcome on Patient's Perception of Physician Compassion | NCT02498899 | Advanced Cancer... | Questionnaires Video | 18 Years - | M.D. Anderson Cancer Center | |
| ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants | NCT02737501 | Non-small Cell ... Lung Cancer Advanced Malign... Carcinoma | Brigatinib Crizotinib | 18 Years - | Takeda | |
| Temsirolimus in Combination With Metformin in Patients With Advanced Cancers | NCT01529593 | Advanced Cancer... | Temsirolimus Metformin | 14 Years - | M.D. Anderson Cancer Center | |
| Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) | NCT01183663 | Advanced Cancer... | Lenalidomide Bevacizumab Sorafenib Temsirolimus Lenalidomide Oxaliplatin Leucovorin 5-fluorouracil | 18 Years - | M.D. Anderson Cancer Center | |
| Rational Therapeutics Based on Matched Tumor and Normal Tissue | NCT02272595 | Advanced Cancer... | Treatment Based... Treatment Based... | 18 Years - | M.D. Anderson Cancer Center | |
| A Pilot Study Treatment of Malignant Tumors Using [18F] Fluorodeoxyglucose (FDG) | NCT02130492 | Advanced Cancer | FDG | 21 Years - | Weill Medical College of Cornell University | |
| Perifosine + Sunitinib Malate for Patients With Advanced Cancers | NCT00399152 | Renal Cancer GIST | Perifosine Sunitinib Malat... | 18 Years - | AEterna Zentaris | |
| Psilocybin in Cancer Pain Study | NCT06001749 | Opioid-Related ... Pain Management Pain Management... Advanced Cancer Advanced Cancer... | Psilocybin | 18 Years - | Dana-Farber Cancer Institute | |
| Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer | NCT01548144 | Advanced Cancer... | Crizotinib (Xal... Pazopanib Pemetrexed | 18 Years - | M.D. Anderson Cancer Center | |
| Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers | NCT00473720 | Advanced Cancer... | Satraplatin Abraxane | 18 Years - | Yale University | |
| BiPAP-Vapotherm RCT | NCT01518140 | Advanced Cancer... | Oxygen Delivery... Questionnaires | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib | NCT01432119 | Advanced Cancer... | SIR-Spheres Cetuximab Erlotinib Break-Through S... | 18 Years - | M.D. Anderson Cancer Center | |
| Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients | NCT02160366 | Advanced Cancer... | Biomarker Resea... | - | M.D. Anderson Cancer Center | |
| Occupational Therapy in Palliative Care | NCT02521194 | Advanced Cancer... | Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| Rational Therapeutics Based on Matched Tumor and Normal Tissue | NCT02272595 | Advanced Cancer... | Treatment Based... Treatment Based... | 18 Years - | M.D. Anderson Cancer Center | |
| Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors | NCT01454804 | Advanced Cancer... | Pazopanib Lapatinib Trastuzumab (He... Pazopanib | - | M.D. Anderson Cancer Center | |
| Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib | NCT01432119 | Advanced Cancer... | SIR-Spheres Cetuximab Erlotinib Break-Through S... | 18 Years - | M.D. Anderson Cancer Center | |
| ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants | NCT02737501 | Non-small Cell ... Lung Cancer Advanced Malign... Carcinoma | Brigatinib Crizotinib | 18 Years - | Takeda | |
| Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) | NCT01183663 | Advanced Cancer... | Lenalidomide Bevacizumab Sorafenib Temsirolimus Lenalidomide Oxaliplatin Leucovorin 5-fluorouracil | 18 Years - | M.D. Anderson Cancer Center | |
| LY2275796 in Advanced Cancer | NCT00903708 | Advanced Cancer... | LY2275796 | 18 Years - | M.D. Anderson Cancer Center | |
| MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies | NCT02042989 | Advanced Cancer... | MLN9708 Vorinostat | 18 Years - | M.D. Anderson Cancer Center | |
| Pilot Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor | NCT01277744 | Advanced Cancer... Sarcoma | Hyperthermic Pe... Cisplatin | 1 Year - | M.D. Anderson Cancer Center | |
| Art Therapy in Palliative Care: Study of Identification and Understanding of the Mechanisms of Change in the Patient | NCT02801045 | Psychological S... Suffering Advanced Cancer... | art therapy | 18 Years - | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | |
| Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L) | NCT01201694 | Advanced Cancer... | Surface-Control... Surface-Control... | 13 Years - | M.D. Anderson Cancer Center | |
| First-in-Human Study of EOS100850 in Patients With Cancer | NCT03873883 | Solid Tumor, Ad... | EOS100850 Pembrolizumab Chemotherapy | 18 Years - | iTeos Therapeutics | |
| A First in Man Study of MABp1 in Patients With Advanced Cancers | NCT01021072 | Advanced Cancer... | MABp1 | 18 Years - | Janssen Research & Development, LLC | |
| Lapatinib With Sirolimus or Metformin | NCT01087983 | Advanced Cancer... | Lapatinib Sirolimus Metformin | - | M.D. Anderson Cancer Center | |
| Hepatic Arterial Infusion (HAI) of Abraxane | NCT00732836 | Liver Cancer Advanced Cancer... Solid Tumors | HAI Abraxane Hepatic Artery ... IV Abraxane | 18 Years - | M.D. Anderson Cancer Center | |
| Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer | NCT01266057 | Advanced Cancer... | Hydroxychloroqu... Sirolimus Vorinostat | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Curcumin, Vorinostat, and Sorafenib | NCT01608139 | Advanced Cancer... | Curcumin Sorafenib Vorinostat | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide | NCT01200004 | Advanced Cancer... | Azacitidine Lenalidomide Grifola Frondos... | 13 Years - | M.D. Anderson Cancer Center | |
| Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies | NCT02668770 | Advanced Cancer... Melanoma | MGN1703 Ipilimumab | 18 Years - | M.D. Anderson Cancer Center | |
| A Pilot Study of Bevacizumab for Neoplastic Meningitis | NCT00924820 | Neoplastic Meni... | Bevacizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab | NCT01213238 | Advanced Cancer... | Oxaliplatin Capecitabine Bevacizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer | NCT01949662 | Advanced Cancer... | Lorazepam Placebo Haloperidol dec... Questionnaires | 18 Years - | M.D. Anderson Cancer Center | |
| Changes in Patient Reported Constipation Among Advanced Cancer Patients After Receiving an Educational Intervention | NCT02422329 | Advanced Cancer... | Questionnaires Video Fact Sheet | 18 Years - | M.D. Anderson Cancer Center | |
| Azacytidine and Valproic Acid in Patients With Advanced Cancers | NCT00496444 | Advanced Cancer... | Azacitidine Valproic Acid | 2 Years - | M.D. Anderson Cancer Center | |
| A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency | NCT02873975 | Advanced Cancer... | LY2606368 | 18 Years - | Dana-Farber Cancer Institute | |
| Erlotinib in Combination With Cetuximab | NCT00895362 | Advanced Cancer... | Erlotinib Cetuximab | 18 Years - | M.D. Anderson Cancer Center | |
| Physician Perceptions About Parenteral Hydration in Latin America and Spain | NCT01011140 | Dehydration Advanced Cancer... | Survey | 18 Years - | M.D. Anderson Cancer Center | |
| Erlotinib in Combination With Pralatrexate in Advanced Malignancies | NCT01532011 | Advanced Cancer... Solid Tumors | Erlotinib Pralatrexate | 12 Years - | M.D. Anderson Cancer Center | |
| Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab | NCT01213238 | Advanced Cancer... | Oxaliplatin Capecitabine Bevacizumab | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Curcumin, Vorinostat, and Sorafenib | NCT01608139 | Advanced Cancer... | Curcumin Sorafenib Vorinostat | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Curcumin, Vorinostat, and Sorafenib | NCT01608139 | Advanced Cancer... | Curcumin Sorafenib Vorinostat | 18 Years - | M.D. Anderson Cancer Center | |
| Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors | NCT01454804 | Advanced Cancer... | Pazopanib Lapatinib Trastuzumab (He... Pazopanib | - | M.D. Anderson Cancer Center | |
| Registry Study for Personalized Cancer Therapy | NCT02508662 | Advanced Cancer... Solid Tumors | Review of Scree... | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide | NCT01200004 | Advanced Cancer... | Azacitidine Lenalidomide Grifola Frondos... | 13 Years - | M.D. Anderson Cancer Center | |
| Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain | NCT02459964 | Advanced Cancer... Pain | Fentanyl Nasal ... Hydromorphone H... Phone Call | - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
